To include your compound in the COVID-19 Resource Center, submit it here.

MM-121: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 25 evaluable patients with refractory advanced solid tumors

Read the full 160 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE